Quarterly ResultMay 7, 2026, 04:24 PM
Caris Q1 Revenue $216.2M (+79%); Net Loss $0.5M; Adj. EBITDA $26.2M
AI Summary
Caris Life Sciences reported strong first-quarter 2026 financial results, with total revenue increasing 79% to $216.2 million and a significant reduction in net loss to $0.5 million. The company achieved positive Adjusted EBITDA of $26.2 million and positive free cash flow of $22.5 million. Operational highlights included the launch of new diagnostic tools like Caris ChromoSeq and Caris MI Clarity, and the reaffirmation of its full-year 2026 revenue guidance of $1.0 billion to $1.02 billion. Clinical therapy selection cases also rose 15% to approximately 52,800.
Key Highlights
- Total revenue grew 79% to $216.2 million for Q1 2026.
- Net loss significantly reduced to $0.5 million from $102.6 million in Q1 2025.
- Achieved positive Adjusted EBITDA of $26.2 million for the quarter.
- Generated positive net cash from operations of $32.9 million.
- Launched Caris ChromoSeq and Caris MI Clarity diagnostic tools.
- Reaffirmed full-year 2026 revenue guidance of $1.0B to $1.02B.
- Clinical therapy selection cases increased 15% to approximately 52,800.
- Gross margin improved to 65%, an 1,800 bps increase.